Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-03
2006-01-03
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254080, C514S256000, C514S419000, C514S183000, C548S469000
Reexamination Certificate
active
06982269
ABSTRACT:
Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivatives and analogues, particularly tetrahydroindolone derivatives or analogues in which the tetrahydroindolone derivative or analogue is covalently linked to another moiety to form a bifunctional conjugate are disclosed. More specifically, methods and compositions for treating attention deficit disorder and attention deficit hyperactivity disorders in adults and children as well as mild cognitive impairment and dementia are provided. The compounds used to treat and/or palliate cognitive/attention deficit disorders in general include a tetrahydroindolone derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring. The moiety A can be a tetrahydroindolone moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.
REFERENCES:
patent: 3300380 (1967-01-01), Glasky et al.
patent: 3321369 (1967-05-01), Glasky et al.
patent: 3438968 (1969-04-01), Glasky et al.
patent: 3666856 (1972-05-01), Ellon et al.
patent: 4035486 (1977-07-01), Laborit
patent: 4138562 (1979-02-01), Vince
patent: 4221794 (1980-09-01), Simon et al.
patent: 4221909 (1980-09-01), Simon et al.
patent: 4221910 (1980-09-01), Giner-Sorolla
patent: 4315920 (1982-02-01), Schaeffer et al.
patent: 4340726 (1982-07-01), Simon et al.
patent: 4347360 (1982-08-01), Ogilvie
patent: 4451478 (1984-05-01), Simon et al.
patent: 4643992 (1987-02-01), Goodman et al.
patent: 4952693 (1990-08-01), Sircar et al.
patent: 4977178 (1990-12-01), Howard et al.
patent: 5023244 (1991-06-01), Goto et al.
patent: 5091432 (1992-02-01), Glasky
patent: 5093318 (1992-03-01), Goodman et al.
patent: 5187162 (1993-02-01), Marangos et al.
patent: 5237051 (1993-08-01), Garbers et al.
patent: 5256677 (1993-10-01), Sham et al.
patent: 5376642 (1994-12-01), Yarchoan et al.
patent: 5447939 (1995-09-01), Glasky
patent: 5565437 (1996-10-01), Marquez et al.
patent: 5595901 (1997-01-01), Rocancourt et al.
patent: 5646300 (1997-07-01), Kosley, Jr. et al.
patent: 5795756 (1998-08-01), Johnson et al.
patent: 5801159 (1998-09-01), Miller et al.
patent: 5801184 (1998-09-01), Glasky et al.
patent: 5948771 (1999-09-01), Danziger
patent: 6027936 (2000-02-01), Glasky
patent: 6630478 (2003-10-01), Diamond et al.
patent: 6630490 (2003-10-01), Diamond et al.
patent: 2002/0040031 (2002-04-01), Glasky et al.
patent: 2002/0040032 (2002-04-01), Glasky et al.
patent: 2002/0128264 (2002-09-01), Taylor
patent: 754681 (1997-01-01), None
patent: WO 99/56550 (1999-11-01), None
patent: WO 99/57119 (1999-11-01), None
patent: WO 99/57120 (1999-11-01), None
patent: WO 99/62899 (1999-12-01), None
patent: WO 99/62899 (1999-12-01), None
patent: WO 01/77075 (2001-10-01), None
patent: WO 01/77075 (2001-10-01), None
patent: WO 02/04448 (2002-01-01), None
patent: WO 02/04448 (2002-01-01), None
K. Nagarajan et al., Synthesis and oral hypoglycemic properties of 4-oxo-4,5,6,7-tetrahydroindole-3-acetic acids. Chemical Abstracts, 1998, vol. 111, Columbus, Ohio.
S.I.Zav'yalov et al., Synthesis of 4,5,6,7-tetrahydroindole derivates. Chemical Abstracts, 2000, vol. 134, Columbus, Ohio.
D.B. Fick et al., Discovery and development of NEO-339, a compound that increases attentional processes associated with improvement in cognition. 28thNational Medicinal Chemistry Symposium, San Diego, CA Jun. 8-12, 2002.
D.R. Helton et al., NEO-339, a novel therapeutic agent for the treatment of mild cognitive impairment and attention deficits. XIVth World Congress of Pharmacology, San Francisco, CA Jul. 7-12, 2002, (Jul. 12, 2002 : presentation / verify by D. Hetton).
D.R. Helton, R.F. Ritzman, V. Fedulov, J.R. Smith, M.M. Foreman, A.J. Glasky, “Effect of NEO-339 on Learning, Memory and Sensorimotor Responsiveness in Young and Aged Mice, ” Abstract 78.17. 31stAnnual Meeting of the Society for Neuroscience, San Diego, CA, Nov. 10-15, 2001.
A. Aurell et al., “The S-100 Protein in Cerebrospinal Fluid: A Simple ELISA Method,”J.Neurol. Sci. 89:157-164 (1989).
A. Dhainaut et al., “New Purines and Purine Analogs as Modulators of Multi-Drug Resistance,”J. Med. Chem. 39:4099-4108 (1996).
A. Nitta et al., “Effects of Oral Administration of a Stimulator for Nerve Growth Factor Synthesis in Basal Forebrain-Lesioned Rats,”Eur. J. Pharmacol. 250:23-30 (1993).
A. Seiger et al., “Intracranial Infusion of Purified Nerve Growth Factor to an Alzheimer Patient: The First Attempt of a Possible Future Treatment Strategy,”Behavioural Brain Res. 57:255-261 (1993).
A. Verma et al., “Carbon Monoxide: A Putative Neural Messenger,”Science249:381-384 (1993).
A. Yamazaki et al., Synthesis of Guanosine and its Derivatives from 5-Amino-1β-D-Ribofuranosyl-4-Imidazolecarboxamide I, Ring Closure with Benzoyl Isothiocyanate,J. Org. Chem. 32:1825-1828 (1967).
A.D. Mooradian, “Effect of Aging on the Blood-Brain Barrier,”Neurbiol. Aging9: 31-39 (1988).
A.E. Miller et al., “Immunological Studies in Senile Dementia of the Alzheimer Type: Evidence for Enhanced Suppressor Cell Activity,”Ann. Neurol. 10:506-510 (1981).
A.G. Gittis & J.R. Puzuasky, “AIT-082 Improves Memory Performance in a Non-Match-to-Sample Task in Rats,”Soc. Neurosci. 25: 62 (1999) (abstract).
A.J. Glasky et al., “Effect of AIT-082, a Purine Analog, on Working Memory in Normal and AGed Mice,”Pharmacol. Biochem. Behav. 47: 325-329 (1994).
A.J. Glasky et al., “Neurotrophins, Growth Factors and Mimetic Agents as Neuroprotectors in the Treatment of Alzheimer's Disease”in Alzheimer Disease: From Molecular Biology to Therapy(R. Becker & E. Giacobini, eds., Birkhäuser, Boston, (1996), pp. 119-124.
A.L. Betz, “Identification of Hypoxanthine Transport and Xanthine Oxidase Activity in Brain Capillaries,”J. Neurochem. 44:574-579 (1985).
B. Alhede et al., “A Simple and Efficient Synthesis of 9-Substituted Guanines. Cyclodesulfurization of 1-Substituted 5-[(Thiocarbamoyl)amino]imidazole-4-carboxamides under Aqueous Basic Conditions,”J. Org. Chem. 56:2139-2143 (1991).
B.H.J. Juurlink et al., “The Hypoxanthine Analogue AIT-082 Bromotes Neurite Formation and Regeneration in Cultured Hippocampal Neurons,”Soc. Neurosci. 24: 1941 (1998) (abstract).
D. Manetti et al., “Design, Synthesis, and Preliminary Pharmacological Evaluation of 1,4-Diazabicyclo[4,3.0]nonan-9-ones as a New Class of Highly Potent Nootropic Drugs,”J. Med. Chem. 43: 1969-1974 (2000).
D. Manetti et al., “Molecular Simplification of 1,4-Diazabicyclo[4,3.0]nonan-9-ones Given Piperazine Derivatives That Maintain High Nootropic Activity,”J. Med. Chem. 43: 4499-4507 (2000).
D. Triguero et al., “Capillary Depletion Method for Quantitation of Blood-Brain Barrier Transport of Circulating Peptides and Plasma Proteins,”J. Neurochem, 54: 1882-1888 (1990).
D.A. Nugiel et al., “Facile Preparation of 2,6-Disubstituted Purines Using Solid Phase Chemistry,”J. Org. Chem.J. Org. Chem, 62:201-203 (1997).
D.H. Maurice & R.J. Haslam, “Molecular Basis of the Synergistic Inhibition of Platelet Function by Nitrovasodilators and Activators of Adenylate Cyclase: Inhibition of Cyclic AMP Breakdown by Cyclic GMP,”Mol. Pharmacol, 37:671-681 (1990).
D.L. Temple, JRL, “Substituted 6,7-Dihydroimidazo[1.2-a] Purin-9 (4H)-ones,”J. Med Chem. 23:1188-1198 (1980).
E.G. Gutierrez et al.,
Fick David B.
Glasky Alvin J.
Helton David
Cullman Louis C.
Kim Vickie
Preston Gates & Ellis LLP
Spectrum Pharmaceuticals Inc.
LandOfFree
Methods for treating cognitive/attention deficit disorders... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cognitive/attention deficit disorders..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cognitive/attention deficit disorders... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3585067